UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/791,219	03/02/2004	Lois Weisman	IOWA:048US	3887
Steven L. Highlander Fulbright & Jaworski L.L.P. Suite 2400 600 Congress Avenue AUSTIN, TX 78701			EXAMINER	
			LIU, SAMUEL W	
			ART UNIT	PAPER NUMBER
			1656	
			MAIL DATE	DELIVERY MODE
			05/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/791,219	WEISMAN, LOIS
Office Action Summary	Examiner	Art Unit
	SAMUEL W. LIU	1656
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLEWHICHEVER IS LONGER, FROM THE MAILING ID. - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by stature Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tind will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on <u>05 I</u> This action is FINAL . 2b) ☑ This action is FINAL . Since this application is in condition for allowated closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro	osecution as to the merits is
Disposition of Claims		
4) ☐ Claim(s) 18-26 and 33-58 is/are pending in the 4a) Of the above claim(s) 18,19 and 24-26 is/s 5) ☐ Claim(s) 18 and 19 is/are allowed. 6) ☐ Claim(s) 24-26 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/s Application Papers 9) ☐ The specification is objected to by the Examin	are withdrawn from consideration.	
10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the lead of a cepted or b) for objected to by the lead of a cepted of the drawing o	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreig a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority document 2. ☐ Certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 3. ☐ Copies of the certified copies of the priority documents 4. ☐ Copies of the priority do	nts have been received. nts have been received in Applicationity documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate

Application/Control Number: 10/791,219 Page 2

Art Unit: 1656

DETAILED ACTION

Status of the claims

Claims 18-26 and 33-58 are pending.

Applicant is advised that the Office action ("Final") mailed 6/1/07 is vacated. The following Office action is applied.

The amendment filed 5/5/08 which cancels claims 1-17, 27-32 and 59-60, and amends claims 24-26 has been entered. Also, the applicant's request (filed 5/5/08) for extension of time of three months has been entered. Claims 33-58 remain withdrawn from further consideration. Claims 18-19 and 24-26 are examined in this Office action.

Withdrawal of objection and rejections

• The objections to claims 18-19 is withdrawn in light of the amendment to claim 18 which delete "non human Vac14 AA" (see the applicants' amendment filed 3/20/07 and the amendment filed 5/5/08).

• The rejection of claims 24-26 under 35 USC 112, second paragraph is withdrawn in light of the amendment to claim 24.

• The rejections of claims 24-26 under 35 USC 112, first paragraph (*Written description and Scope enablement*) are withdrawn in light of that the applicant's arguments set forth in the response filed 12/03/07 and the "Appeal brief" filed 5/5/08" are persuasive.

• The rejection of claims 24-26 under 35 USC 102(e) by Robert et al. is withdrawn in light of the amendment of claims 24-26.

New-Claim Rejections - 35 USC §103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Page 3

Claims 24-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Drmanac et al. (WO 0175067 A2).

In patent claim 20, Drmanac et al. disclose an isolated polypeptide of SEQ ID NO:51018 which amino acid residues 90-163 has sequence identity to residues 23-96 of instant SEQ ID NO:3 (see the "attachment" labeled "10791219 SEQ Align"). Also, at page 9, lines 12-20, Drmanac et al. further teach a fragment of the disclosed polypeptide wherein said "fragment" is preferably at least 17 amino acids, which is applied to claim 24.

Because Drmanac et al. teach that the "fragment" is preferably 17 or more amino acids (see page 9, lines 16-17); this encompasses peptide fragments of 20 or 25 or 30 residues in length; and thus, said "fragment" is an obvious variation of instant "oligopeptide" of claims 25 and 16.

Although Drmanac et al. do not expressly or directly disclose the oligopeptide comprising 15 consecutive residues of instant SEQ ID NO:3, it would have been obvious to one of ordinary skill in the art that the fragment can be 15, 20, 25 or 30 residues in length. This is because Drmanac et al. have taught that the "fragment" is preferably at least 17 amino acids and preferably less than 100 amino acid (page 9, lines 16 and 18). Within this narrow range: $15 \le \text{length} \le 100$ (note that the "oligopeptide" of claim 24 is in a range of length ""between 15 and 30 residues"), with the aid of a computer, one skilled in the art would have readily made the

Application/Control Number: 10/791,219 Page 4

Art Unit: 1656

oligopeptides which have immunological activity (see page 9, line 20) and which have obviously

included those consisting of 15, 20, 25 or 30 residues in length with reasonable expectation of

success.

Conclusion

Claims 17-18 are free from prior art, and claims 24-26 are not allowed.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Samuel Wei Liu whose telephone number is 571-272-0949. The

examiner can normally be reached from 9:00 a.m. to 5:00 p.m. on weekdays. If attempts to reach

the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr Bragdon,

can be reached on (571) 272-0931. The fax phone number for the organization where this

application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval IPAIRI system. Status information for published applications may

be obtained from either Private PAIR or Public PAG. Status information for unpublished applications

is available through Private PAG only. For more information about the PAN system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the

Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Samuel W Liu, Ph.D./

Examiner, Art Unit 1656

May 21, 2008

/Karen Cochrane Carlson, Ph.D./

Primary Examiner, Art Unit 1656

Application/Control Number: 10/791,219

Page 5

Art Unit: 1656